Basic HTML Version
23
Forum Medycyny Rodzinnej 2012, tom 6, nr 1, 14–23
Iwona Damps-Konstańska i wsp.
Zintegrowany model opieki nad
chorymi na przewlekłą obturacyjną
chorobę płuc (POChP) w praktyce
lekarza rodzinnego
19. Eriksen N., Vestbo J. Management and survival
of patients admitted with an exacerbation of
COPD: comparison of two Danish patient co-
horts. Clin. Respir. J. 2010; 4: 208–214.
20. Jahnz-Różyk K., Targowski T., From S. Costs of
exacerbation of chronic obstructive pulmonary
disease in primary and secondary care in 2007
— results from multicenter study. Pol. Merk. Lek.
2009; 26: 208–214.
21. Seemungal T.A., Hurst J.R., Wedzicha J. Exacer-
bation rate, health status and mortality in COPD
— a review of potential interventions. Int. J. COPD
2009; 4: 203–223.
22. Hurst J.R., Vestbo J., Anzueto A. i wsp. Suscep-
tibility to exacerbation in chronic obstructive pul-
monary disease. NEJM 2010; 363: 1128–1138.
23. Jones P.W., Brusselle G., Dal Negro R.W. i wsp.
Properties of the COPD assessment test in the
cross-sectional European study. Eur. Respir. J.
2011; 38: 29–35.
24. Vestbo J., Edwards L.D., Scanlon P.D. i wsp.
Changes in forced expiratory volume in 1 second
over time in COPD. NEJM 2011; 365: 1184–1192.
25. Kesten S., Celli B., Decramer M. i wsp. Adverse
health consequences in COPD patients with ra-
pid decline in FEV1 — evidence from the UPLIFT
trial. Respir. Res. 2011; 12: 129.
26. Seemungal T.A., Donaldson G.C., Bhowmik A.
i wsp. Time course and recovery of exacerbation
in patients with chronic obstructive pulmonary
disease. Am. J. Crit. Care Respir. Med. 2000;
161: 1608–1613.
27. Donaldson G.C. i wsp. Relationship between exa-
cerbation frequency and lung function decline in
chronic obstructive pulmonary disease. Thorax
2002; 57: 847–852.
28. Zieliński J., Tobiasz M., Hawryłkiewicz I. i wsp.
Effects of long-term oxygen therapy on pulmona-
ry hemodynamics in COPD patients. Chest 1998;
113: 65–70.
29. Nocturnal Oxygen Therapy Trial Group. Continu-
ous or nocturnal oxygen therapy m hypoxemic
chronic obstructive lung disease: a clinical trial.
Ann. Intern. Med. 1980; 93: 391–398.
30. Levy M., Tanios M.A., Nelson D. i wsp. Outcomes
of patients with do-not-intubate orders treated
with noninvasive ventilation. Crit. Care Med.
2004; 32: 2002–2007.
31. Schettino G., Altobelli N., Kacmarek R.M. Noni-
nvasive positive pressure ventilation reverses acu-
te respiratory failure in selected ‘‘do-not-intubate’’
patients. Crit. Care Med. 2005; 33: 1976–1982.
32. Chu C.-M., Chan V.L., Wong I.W.Y. i wsp. Noni-
nvasive ventilation in patients with acute hyper-
capnic exacerbation of chronic obstructive pul-
monary disease who refused endotracheal intu-
bation. Crit. Care Med. 2004; 32: 372–377.
33. Bott J., Carrol M.P., Conway J.H. i wsp. Rando-
mised controlled trial of nasal ventilation in acu-
te ventilatory failure due to chronic obstructive
airways disease. Lancet 1993; 341: 1555–1557.
34. Antoniu S.A. Predictors of depression in chronic
obstructive pulmonary disease patients. Expert.
Rev. Respir. Med. 2011; 5: 333–335.
35. Wilkinson T.M., Donaldson G.C., Hurst J.R. i wsp.
Early therapy improves outcomes of exacerba-
tions in chronic obstructive pulmonary disease.
AJRCCM 2004; 169: 1298–1303.
36. Kessler R., Stahl E., Vogelmeier C. i wsp. Patients
understanding, detection and experience of
COPD exacerbations: an observational, inte-
rview-based study. Chest 2006; 130: 133–142.
37. Walters J.A., Turnock A.C., Walters E.H., Wood-
-Baker R. Action plans with limited patients edu-
cation only exacerbations of chronic obstructive
pulmonary disease. Cochrane Database Rev.
2009, CD005074.
38. Hryniewicz W., Ozorowski T., Radzikowski A.
i wsp. Rekomendacje postępowania w pozasz-
pitalnych zakażeniach układu oddechowego.
Narodowy Program Oszczędzania Antybiotyków
2010.
39. Walters J.A., Gibson P.G., Wood-Baker R. i wsp.
Systemic corticosteroids for acute exacerbation
of chronic obstructive pulmonary disease. Co-
chrane Database Syst. Rev. 2009; CD001288.
40. Garcia-Aymerich J., Hernandez C., Alonso A.
i wsp. Effects of an integrated care intervention
on risk factors of COPD readmission. Respir.
Med. 2007; 101: 1462–1469.
41. Lareau S.C., Yawn B.P. Improving adherence
with inhaler therapy in COPD. Int. J. COPD 2010;
5: 401–406.
42. Breekveldt-PostmaN.S., Koerselman J., Erkens J.A.
i wsp. Enhance persistence of tiotropium compa-
red with other respiratory drugs in COPD. Respi-
ro. Med. 2007; 101: 1398–1405.
43. Cramer J.A., Bradley-Kennedy C., Scalera A. Tre-
atment persistence and compliance with medica-
tions for chronic obstructive pulmonary disease.
Can. Respir. J. 2007; 14: 25–29.
44. Binnebesel J., Janowicz A., Krakowiak P., Pacz-
kowska A. (red.). Pozamedyczne aspekty opieki
paliatywno-hospicyjnej. Via Medica, Gdańsk
2010.
45. Jassem E., Górecka D., Krakowiak P. i wsp. Zin-
tegrowana opieka medyczna u chorych na za-
awansowane postaci ciężkiej obturacyjnej cho-
roby płuc (POChP). Pneumonol. Alergol. Pol.
2010; 78: 126–132.
46. Jassem E., Kozielski J., Górecka D. i wsp. Inte-
grated care for patients with advanced chronic
obstructive pulmonary disease: a New approach
to organization. Pol. Arch. Med. Wewn. 2010;
120: 423–427.
47. Krakowiak P., Krzyżanowski D., Modlinska A.
(red.). Przewlekle chory w domu. Via Medica,
Gdańsk 2011.